Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406957 | 0.90 | CA12 (0.61) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL1951310 | 0.83 | CA12 (0.56) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL1947879 | 0.82 | ALDH1A1 (0.65) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL28179229 | 0.82 | CA12 (0.59) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL2918702 | 0.82 | GAA (0.64) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL11100708 | 0.82 | CA12 (0.63) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL9972673 | 0.81 | CA12 (0.49) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL1840737 | 0.81 | ALDH1A1 (0.62) | NPC1RAB9AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4756378 | 0.81 | CA12 (0.58) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL28347887 | 0.80 | CA12 (0.61) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | ALKBH3, ALKBH1, ALKBH2 | CA12 745/4885CA1 633/4885CA2 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.